AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Inclusion Criteria:

   - Pathologically confirmed adenocarcinoma of the prostate

   - Radiographic evidence of metastatic disease

   - Progressive disease meeting at least one of the following criteria:

      1. a sequence of at least 2 rising PSA values measured at a minimum of 1 week apart
      with a 2 ng/mL minimum starting value, or

      2. progression according to RECIST criteria for measurable lesions, or

      3. appearance of 2 or more new lesions on bone scan.

   - History of prior taxane-based chemotherapy for metastatic prostate cancer

   - For patients without a history of surgical castration, continued GnRH analog
   administration is required

   - ECOG Performance status of 0 or 1

   - Life expectancy ≥ 3 months

Exclusion Criteria:

   - Treatment with external beam radiotherapy ≤ 14 days before enrollment or
   radiopharmaceutical ≤8 weeks

   - ≤ 4 weeks since receipt of most recent prior chemotherapy, non-GnRH analog hormonal
   therapy (except for continuing corticosteroids) or other systemic therapy to treat
   prostate cancer and <6 weeks since receipt of prior bevacizumab.

   - Known CNS metastases (epidural disease is allowed if it has been treated and there is
   no progression in the treated area).

   - Significant cardiovascular disease

   - LVEF < 50% by MUGA or ECHO

   - Treatment of infection with systemic anti-infectives within 7 days before enrollment
   (with the exception of uncomplicated urinary tract infection)

   - Concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except that
   use of low dose coumarin-type anticoagulants or heparins for prophylaxis against
   central venous catheter thrombosis is allowed

   - Major surgical procedure ≤30 days before enrollment or not yet recovered from prior
   major surgery

   - Presence of peripheral edema > Grade 2

   - Known positive test for HIV, hepatitis C, chronic or active hepatitis B

   - Serious or non-healing wound

   - Unable to begin protocol specified treatment within 7 days after enrollment

   - Other investigational procedures are excluded.